Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Novo Nordisk's (NVO) downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ability to maintain a market lead in the obesity drug space. The maker ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to have contributed to something that’s helped so many.

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

As a reporter, I've covered all things GLP-1. Here's what I've learned. From protein hacks to thinness myths, my reporting journey has been full of surprises.

Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers ...

Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged ... While some employers have covered GLP-1s, hoping for long-term health savings, rising prices are forcing a ...

Express Scripts — Cigna's pharmacy benefit manager — said Thursday that it will expand low-copay access to GLP-1 agonist weight-loss drugs for participants in some of the prescription drug ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...